Literature DB >> 19532105

Cardiomyopathy and the dilemma of geometric mitral regurgitation.

Mandeep R Mehra1, Patricia A Uber, Roberto M Benitez.   

Abstract

PURPOSE OF REVIEW: Geometric mitral regurgitation is a phenomenon encountered by an otherwise anatomically normal mitral valve in the setting of advanced adverse left ventricular remodeling that alters the alignment characteristics of the mitral valve apparatus leading to functional production of a leaking valve. In this review, we discuss contemporary directions in the knowledge base for managing geometric mitral regurgitation. RECENT
FINDINGS: Much progress has been encountered in describing the types of geometric mitral regurgitation (nonischemic and ischemic origins), standardization of echocardiographic techniques to allow for a common language in ascertaining the severity of mitral regurgitation, knowledge on dynamic mitral regurgitation during exercise, effectiveness of therapy and appropriate use and timing of surgical repair.
SUMMARY: Geometric mitral regurgitation develops in tandem with progressive ischemic or nonischemic cardiomyopathy and can improve with antiremodeling pharmacological and device-based therapy. Surgical therapy can be accomplished at experienced centers with low morbidity and mortality, and may improve symptoms and enhance pump function. Whether such therapy saves lives remains uncertain. New percutaneous approaches to tackle geometric mitral regurgitation are developing, and early data is encouraging but remains experimental.

Entities:  

Mesh:

Year:  2009        PMID: 19532105     DOI: 10.1097/HCO.0b013e3283257a47

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  1 in total

1.  An echocardiographic evaluation of valvular function and ventricular patch repair during surgical exclusion of left ventricular pseudoaneurysm.

Authors:  Rory D O'Donoghue; Andra E Duncan; Thomas G Fraser; James D Thomas
Journal:  Anesth Analg       Date:  2011-08-04       Impact factor: 5.108

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.